OmniAb Inc
NASDAQ:OABI
OmniAb Inc
OmniAb, Inc. operates as a drug discovery company. The company is headquartered in Emeryville, California and currently employs 93 full-time employees. The company went IPO on 2020-10-09. The OmniAb platform is the biological intelligence (BI) of transgenic animals, including OmniRat, OmniChicken, and OmniMouse, which have been genetically modified to generate antibodies with human sequences to facilitate the development of human therapeutic candidates. Its OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications through a common light chain approach and OmniTaur features structural attributes of cow antibodies for complex targets. The firm's OmniChicken and OmniClic offer affinity-matured antibodies in an evolutionarily distant chicken host environment, which can deliver a diverse repertoire of antibody panels to conserved therapeutic targets.
OmniAb, Inc. operates as a drug discovery company. The company is headquartered in Emeryville, California and currently employs 93 full-time employees. The company went IPO on 2020-10-09. The OmniAb platform is the biological intelligence (BI) of transgenic animals, including OmniRat, OmniChicken, and OmniMouse, which have been genetically modified to generate antibodies with human sequences to facilitate the development of human therapeutic candidates. Its OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications through a common light chain approach and OmniTaur features structural attributes of cow antibodies for complex targets. The firm's OmniChicken and OmniClic offer affinity-matured antibodies in an evolutionarily distant chicken host environment, which can deliver a diverse repertoire of antibody panels to conserved therapeutic targets.
Revenue Decline: Q3 2025 revenue fell to $2.2 million, down from $4.2 million last year, mainly due to fewer milestones and lower service revenue.
Cost Reductions: Operating expenses dropped to $20.4 million from $23.9 million, driven by lower R&D and G&A costs and a headcount reduction.
Cash Bolstered: OmniAb closed a $30 million private placement, ending the quarter with $59.5 million in cash, and expects to finish the year with $52–56 million.
Guidance Lowered: 2025 revenue guidance was cut to $18–22 million due to milestone delays; operating expense guidance was also reduced.
Strong Program Additions: 2025 program additions have already matched all of 2024, with 104 active partners and 399 active programs.
New Technology Launch: OmniUltra, a transgenic chicken platform for novel antibody and peptide therapeutics, will launch in December.
xPloration Momentum: The xPloration platform is gaining traction, with positive partner feedback and expectations for accretive revenue and cash flow.
